よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (49 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
51. Derrick C, et al. Multicenter, Observational Cohort Study Evaluating Third-Generation
Cephalosporin Therapy for Bloodstream Infections Secondary to Enterobacter, Serratia,
and Citrobacter Species. 2020. 9(5):254.
4
5
6
52. Mounier R, et al. Clinical outcome of wild-type AmpC-producing Enterobacterales
infection in critically ill patients treated with β-lactams: a prospective multicenter study.
Ann Intensive Care. 2022. 12(1):107.
7
8
9
53. Petit M, et al. Antibiotic definitive treatment in ventilator associated pneumonia caused
by AmpC-producing Enterobacterales in critically ill patients: a prospective multicenter
observational study. Crit Care. 2024. 28(1):40.
10
11
12
54. Choi SH, et al. Emergence of antibiotic resistance during therapy for infections caused
by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use.
Antimicrob Agents Chemother. 2008. 52(3):995-1000.
13
14
15
55. Carrié C, et al. Piperacillin-tazobactam should be preferred to third-generation
cephalosporins to treat wild-type inducible AmpC-producing Enterobacterales in critically
ill patients with hospital or ventilator-acquired pneumonia. J Crit Care. 2020. 56:6-11.
16
17
18
19
20
56. Stewart AG, et al. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment
of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp,
Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A
Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infect Dis.
2021. 8(8):ofab387.
21
22
23
24
57. Lu B, et al. Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-nonsusceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia
marcescens and Morganella morganii bacteraemia in immunocompromised patients. J
Antimicrob Chemother. 2023. 78(4):1009-1014.
25
26
27
58. Cheng L, et al. Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment
of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae.
Antimicrob Agents Chemother. 2017. 61(6):e00276-17.
28
29
30
31
59. Meije Y, et al. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of
bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase
(ESBL) or AmpC β-lactamase: A propensity score study. Int J Antimicrob Agents. 2019.
54(2):189-196.
32
33
60. Maan G, et al. Cefepime-induced neurotoxicity: systematic review. J Antimicrob
Chemother 2022. 77(11):2908-2921.
34
35
36
61. Kunz Coyne AJ, et al. High-dose Cefepime vs Carbapenems for Bacteremia Caused by
Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase
Production. Open Forum Infect Dis. 2023. 10(3):ofad034.
37
38
39
62. Tamma PD, et al. Association of 30-Day Mortality With Oral Step-Down vs Continued
Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.
JAMA Intern Med. 2019. 179(3):316-323.
40
41
63. 厚生労働省 カルバペネム耐性腸内細菌科細菌感染症. at
https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-140912-1.html.)
42
43
44
64. 56-1. 厚生労働省. 健康・生活衛生局感染症対策部 感染症対策課. 5 類感染症に指定され
ている薬剤耐性菌感染症の検討. 第 92 回厚生科学審査会感染症部会 資料 2. 2024 年 12
月 13 日. https://www.mhlw.go.jp/content/10906000/001352580.pdf
49
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
51. Derrick C, et al. Multicenter, Observational Cohort Study Evaluating Third-Generation
Cephalosporin Therapy for Bloodstream Infections Secondary to Enterobacter, Serratia,
and Citrobacter Species. 2020. 9(5):254.
4
5
6
52. Mounier R, et al. Clinical outcome of wild-type AmpC-producing Enterobacterales
infection in critically ill patients treated with β-lactams: a prospective multicenter study.
Ann Intensive Care. 2022. 12(1):107.
7
8
9
53. Petit M, et al. Antibiotic definitive treatment in ventilator associated pneumonia caused
by AmpC-producing Enterobacterales in critically ill patients: a prospective multicenter
observational study. Crit Care. 2024. 28(1):40.
10
11
12
54. Choi SH, et al. Emergence of antibiotic resistance during therapy for infections caused
by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use.
Antimicrob Agents Chemother. 2008. 52(3):995-1000.
13
14
15
55. Carrié C, et al. Piperacillin-tazobactam should be preferred to third-generation
cephalosporins to treat wild-type inducible AmpC-producing Enterobacterales in critically
ill patients with hospital or ventilator-acquired pneumonia. J Crit Care. 2020. 56:6-11.
16
17
18
19
20
56. Stewart AG, et al. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment
of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp,
Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A
Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infect Dis.
2021. 8(8):ofab387.
21
22
23
24
57. Lu B, et al. Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-nonsusceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia
marcescens and Morganella morganii bacteraemia in immunocompromised patients. J
Antimicrob Chemother. 2023. 78(4):1009-1014.
25
26
27
58. Cheng L, et al. Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment
of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae.
Antimicrob Agents Chemother. 2017. 61(6):e00276-17.
28
29
30
31
59. Meije Y, et al. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of
bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase
(ESBL) or AmpC β-lactamase: A propensity score study. Int J Antimicrob Agents. 2019.
54(2):189-196.
32
33
60. Maan G, et al. Cefepime-induced neurotoxicity: systematic review. J Antimicrob
Chemother 2022. 77(11):2908-2921.
34
35
36
61. Kunz Coyne AJ, et al. High-dose Cefepime vs Carbapenems for Bacteremia Caused by
Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase
Production. Open Forum Infect Dis. 2023. 10(3):ofad034.
37
38
39
62. Tamma PD, et al. Association of 30-Day Mortality With Oral Step-Down vs Continued
Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.
JAMA Intern Med. 2019. 179(3):316-323.
40
41
63. 厚生労働省 カルバペネム耐性腸内細菌科細菌感染症. at
https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-140912-1.html.)
42
43
44
64. 56-1. 厚生労働省. 健康・生活衛生局感染症対策部 感染症対策課. 5 類感染症に指定され
ている薬剤耐性菌感染症の検討. 第 92 回厚生科学審査会感染症部会 資料 2. 2024 年 12
月 13 日. https://www.mhlw.go.jp/content/10906000/001352580.pdf
49